Cellectis (NASDAQ:CLLS) Azioni, Quote.MetaTitle.unusual-options

Cellectis

Cellectis S.A. - American Depositary Shares

Panoramica

Notizie

Utili

Opzioni

Valutazioni degli analisti

Vendite allo scoperto

Rapporto azionario

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.

Comments

Cellectis Opzioni Inusuali

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO